drugset / Trial / NCT04777162
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
NaSingle-groupOpen-labelTreatment
Summary
Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.
Timeline
- Start
- 2021-03
- Primary completion
- 2023-01
- Completion
- 2023-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |